Literature DB >> 24186313

Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease.

Enrico M Novelli1, Gregory J Kato, Mariana E Hildesheim, Suchitra Barge, Michael P Meyer, Jay Lozier, Andrea Cortese Hassett, Margaret V Ragni, Jeffrey S Isenberg, Mark T Gladwin.   

Abstract

Entities:  

Keywords:  ADAMTS13; acute chest syndrome; sickle cell disease

Mesh：

Substances：

Year:  2013        PMID： 24186313      PMCID： PMC3815185          DOI： 10.3324/haematol.2013.092635

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Sickle cell vaso-occlusion: multistep and multicellular paradigm.

Authors:  Paul S Frenette
Journal:  Curr Opin Hematol       Date:  2002-03       Impact factor: 3.284

Review 2.  The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47.

Authors:  David D Roberts; Thomas W Miller; Natasha M Rogers; Mingyi Yao; Jeffrey S Isenberg
Journal:  Matrix Biol       Date:  2012-01-14       Impact factor: 11.583

3.  Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.

Authors:  Arnaud Bonnefoy; Kim Daenens; Hendrik B Feys; Rita De Vos; Petra Vandervoort; Jos Vermylen; Jack Lawler; Marc F Hoylaerts
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

4.  Thrombotic thrombocytopenic purpura in a patient with sickle cell crisis.

Authors:  J Bolaños-Meade; Y K Keung; C López-Arvizu; R Florendo; E Cobos
Journal:  Ann Hematol       Date:  1999-12       Impact factor: 3.673

5.  Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease.

Authors:  Zhou Zhou; Hyojeong Han; Miguel A Cruz; José A López; Jing-Fei Dong; Prasenjit Guchhait
Journal:  Thromb Haemost       Date:  2009-06       Impact factor: 5.249

6.  Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia.

Authors:  Suba Krishnan; Jamie Siegel; Gene Pullen; Megan Hevelow; Carlton Dampier; Marie Stuart
Journal:  Thromb Res       Date:  2008-01-29       Impact factor: 3.944

7.  Thrombotic thrombocytopenic purpura and sickle cell crisis.

Authors:  Suresh G Shelat
Journal:  Clin Appl Thromb Hemost       Date:  2008-10-07       Impact factor: 2.389

8.  Plasma exchange in critically ill patients with sickle cell disease.

Authors:  C Boga; I Kozanoglu; H Ozdogu; Emel Ozyurek
Journal:  Transfus Apher Sci       Date:  2007-08-17       Impact factor: 1.764

9.  Life-threatening thrombotic thrombocytopenic purpura (TTP) in a patient with sickle cell-hemoglobin C disease.

Authors:  H E Lee; V J Marder; L J Logan; S Friedman; B J Miller
Journal:  Ann Hematol       Date:  2003-08-16       Impact factor: 3.673

10.  Disturbance of plasma and platelet thrombospondin levels in sickle cell disease.

Authors:  P V Browne; D F Mosher; M H Steinberg; R P Hebbel
Journal:  Am J Hematol       Date:  1996-04       Impact factor: 10.047
View more
  14 in total

Review 1.  Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.

Authors:  Ram Kalpatthi; Enrico M Novelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Vascular TSP1-CD47 signaling promotes sickle cell-associated arterial vasculopathy and pulmonary hypertension in mice.

Authors:  Enrico M Novelli; Lynda Little-Ihrig; Heather E Knupp; Natasha M Rogers; Mingyi Yao; Jeffrey J Baust; Daniel Meijles; Claudette M St Croix; Mark A Ross; Patrick J Pagano; Evan R DeVallance; George Miles; Karin P Potoka; Jeffrey S Isenberg; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-03-20       Impact factor: 5.464

Review 3.  The multifaceted role of ischemia/reperfusion in sickle cell anemia.

Authors:  Robert P Hebbel; John D Belcher; Gregory M Vercellotti
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

4.  Endothelial VWF is critical for the pathogenesis of vaso-occlusive episode in a mouse model of sickle cell disease.

Authors:  Huiping Shi; Bojing Shao; Liang Gao; Thamizhiniyan Venkatesan; John Michael McDaniel; Meixiang Zhou; Samuel McGee; Pengchun Yu; Jasimuddin Ahamed; Janna Journeycake; James N George; Lijun Xia
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-15       Impact factor: 12.779

Review 5.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

6.  Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.

Authors:  Anwar Al-Awadhi; Adekunle Adekile; Rajaa Marouf
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

Review 7.  Thrombospondin-1 in maladaptive aging responses: a concept whose time has come.

Authors:  Jeffrey S Isenberg; David D Roberts
Journal:  Am J Physiol Cell Physiol       Date:  2020-05-06       Impact factor: 4.249

8.  Clinical significance of assessment of thrombospondin and placenta growth factor levels in patients with sickle cell anemia: two centers egyptian studies.

Authors:  Adel A Hagag; Ghada Elmashad; Aml Ezzat Abd El-Lateef
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-07-01       Impact factor: 2.576

9.  Pulmonary platelet thrombi and vascular pathology in acute chest syndrome in patients with sickle cell disease.

Authors:  Ciprian B Anea; Matthew Lyon; Itia A Lee; Joyce N Gonzales; Amidat Adeyemi; Greer Falls; Abdullah Kutlar; Julia E Brittain
Journal:  Am J Hematol       Date:  2016-02       Impact factor: 10.047

10.  Increased Vasoocclusive Crises in "O" Blood Group Sickle Cell Disease Patients: Association with Underlying Thrombospondin Levels.

Authors:  M Al Huneini; S Alkindi; V Panjwani; K Al Falahi; B Al Balushi; D Gravell; C H Ho; R Krishnamoorthy; A V Pathare
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-04-20       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.